



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Brand et al.

SERIAL NUMBER: 10/691,123

EXAMINER: Marcela M. Cordero Garcia

FILING DATE: October 22, 2003

ART UNIT: 1654

FOR: TREATMENT OF DIABETES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO MARCH 21, 2006 OFFICE ACTION AND PRELIMINARY
AMENDMENT**

In response to the March 21, 2006 Office Action imposing restriction and species election, Applicants elect Group I, which includes claims 1-4, 7-10, 12-14, 24-26, 33-45, 101-107, and 110. Applicants elect the species Glucagon 1-like peptide receptor ligand (GLP-1) (FACGINT), gastrin (gastrin/CCK receptor ligand), and rapamycin (immunosuppressive agent). Claims 1-4, 7-10, 12-14, 24-26, 33-45, 101-107, and 110 read on the elected species GLP-1, gastrin, and rapamycin.

Amendments to the claims begin on page 2.

Remarks begin on page 8.